Selected article for: "RBD interaction and SARS recognition"
Author: Souza, Pedro F. N.; Amaral, Jackson L.; Bezerra, Leandro P.; Lopes, Francisco E. S.; Freire, Valder N.; Oliveira, Jose T. A.; Freitas, Cleverson D. T.
Title: ACE2-derived peptides interact with the RBD domain of SARS-CoV-2 spike glycoprotein, disrupting the interaction with the human ACE2 receptor
  • Cord-id: pzpc9f5w
  • Document date: 2021_1_10
    • ID: pzpc9f5w
    Snippet: Vaccines could be the solution to the current SARS-CoV-2 outbreak. However, some studies have shown that the immunological memory only lasts three months. Thus, it is imperative to develop pharmacological treatments to cope with COVID-19. Here, the in silico approach by molecular docking, dynamic simulations and quantum biochemistry revealed that ACE2-derived peptides strongly interact with the SARS-CoV-2 RBD domain of spike glycoprotein (S-RBD). ACE2-Dev-PepI, ACE2-Dev-PepII, ACE2-Dev-PepIII an
    Document: Vaccines could be the solution to the current SARS-CoV-2 outbreak. However, some studies have shown that the immunological memory only lasts three months. Thus, it is imperative to develop pharmacological treatments to cope with COVID-19. Here, the in silico approach by molecular docking, dynamic simulations and quantum biochemistry revealed that ACE2-derived peptides strongly interact with the SARS-CoV-2 RBD domain of spike glycoprotein (S-RBD). ACE2-Dev-PepI, ACE2-Dev-PepII, ACE2-Dev-PepIII and ACE2-Dev-PepIV complexed with S-RBD provoked alterations in the 3D structure of S-RBD, leading to disruption of the correct interaction with the ACE2 receptor, a pivotal step for SARS-CoV-2 infection. This wrong interaction between S-RBD and ACE2 could inhibit the entry of SARS-CoV-2 in cells, and thus virus replication and the establishment of COVID-19 disease. Therefore, we suggest that ACE2-derived peptides can interfere with recognition of ACE2 in human cells by SARS-CoV-2 in vivo. Bioinformatic prediction showed that these peptides have no toxicity or allergenic potential. By using ACE2-derived peptides against SARS-CoV-2, this study points to opportunities for further in vivo research on these peptides, seeking to discover new drugs and entirely new perspectives to treat COVID-19. Communicated by Ramaswamy H. Sarma

    Search related documents:
    Co phrase search for related documents
    • accession number and acute sars cov respiratory syndrome coronavirus: 1, 2, 3
    • accession number and lung heart: 1
    • accession number and lung heart liver: 1
    • acute sars cov respiratory syndrome coronavirus and long helix: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and low blood pressure: 1
    • acute sars cov respiratory syndrome coronavirus and low energy: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute sars cov respiratory syndrome coronavirus and low interaction energy: 1
    • acute sars cov respiratory syndrome coronavirus and low normal: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute sars cov respiratory syndrome coronavirus and low stability: 1, 2, 3, 4, 5, 6
    • acute sars cov respiratory syndrome coronavirus and low toxicity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • acute sars cov respiratory syndrome coronavirus and lung heart: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62
    • acute sars cov respiratory syndrome coronavirus and lung heart liver: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute sars cov respiratory syndrome coronavirus and lung heart liver brain: 1, 2, 3, 4, 5, 6, 7
    • acute sars cov respiratory syndrome coronavirus and lung heart liver brain gut: 1, 2
    • acute sars cov respiratory syndrome coronavirus and lung heart liver brain gut kidney: 1
    • low blood pressure and lung heart: 1, 2